BioSpace

Novartis projects slowed growth, pins hopes on billions in pipeline potential

With Kisqali going off patent and decreasing prices impacting sales, Novartis has narrowed sales guidance to 5% growth. But management remains steadfast that they have a plan to get back on track.

By BioSpace

1 min read
Novartis projects slowed growth, pins hopes on billions in pipeline potential
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights